Gastrointestinal Cancers

Combining Sorafenib and Transarterial Chemoembolization Extends Progression-Free Survival in Patients with Hepatocellular Carcinoma

Wayne Kuznar

June 2018, Vol 8, No 6 - Gastrointestinal Cancers

Sorafenib (Nexavar) in combination with transcatheter ­arterial chemoembolization (TACE) significantly improves progression-free survival (PFS), with no unexpected adverse results, compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), according to results from the phase 2 TACTICS clinical trial. [ Read More ]